Top Markets
Coin of the day
AlloVir, Inc. AlloVir, Inc.

AlloVir, Inc.

ALVR
Pozycja w akcjach #25523
AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to... AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.
Cena akcji
$9.81
Ostatnia synchronizacja: 2025-03-18
Kapitalizacja rynkowa
$48.68M
Zmiana (1 dzień)
1.55%
Zmiana (1 rok)
0.00%
Kraj
US
Handel AlloVir, Inc. (ALVR)

Kategoria

Historia ceny akcji dla AlloVir, Inc. (ALVR)
Najwyższa cena zamknięcia: $9.65 dnia 2025-03-01

Najniższa cena zamknięcia: $578.34 dnia 2020-07-01
Historia cen akcji firmy AlloVir, Inc. od 2020 do 2026
Roczna wydajność ceny akcji
Rok Wydajność
2025 -11.26%
2024 -74.50%
2023 -70.35%
2022 -60.21%
2021 -61.81%
2020 0.00%
Cena akcji podobnych firm lub konkurencji
Firma Cena akcji Zmiana 1r% Kraj
$539.14 35.65%
US
$1.04K 56.21%
NL
$118.33 -18.49%
AU
$761.87 8.65%
CH
$130.43 397.46%
US